Sana Biotechnology Inc
SANA
Company Profile
Business description
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Contact
188 East Blaine Street
Suite 400
SeattleWA98102
USAT: +1 206 701-7914
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
194
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors overly negative on cheap ASX share
We cut our fair value by 26% but the market has overreacted.
stocks
Overvalued US AI play reports earnings
Strong earnings with high projected growth but price is too rich.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.40 | 6.00 | 0.07% |
| CAC 40 | 8,151.38 | 0.74 | 0.01% |
| DAX 40 | 24,288.40 | 88.90 | 0.37% |
| Dow JONES (US) | 48,134.89 | 183.04 | 0.38% |
| FTSE 100 | 9,897.42 | 59.65 | 0.61% |
| HKSE | 25,690.53 | 192.40 | 0.75% |
| NASDAQ | 23,307.62 | 301.26 | 1.31% |
| Nikkei 225 | 49,507.21 | 505.71 | 1.03% |
| NZX 50 Index | 13,447.48 | 114.08 | 0.86% |
| S&P 500 | 6,834.50 | 59.74 | 0.88% |
| S&P/ASX 200 | 8,668.20 | 8.00 | 0.09% |
| SSE Composite Index | 3,890.45 | 14.08 | 0.36% |